Randomized phase II study of bortezomib, thalidomide and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.

Ludwig H, Viterbo L, Greil R, Masszi T, Spicka I, Shpilberg O, Hajek R, Dmoszynska A, Paiva B, Vidriales MB, Esteves G, Stoppa AM, Robinson D Jr, Ricci D, Cakana A, Enny C, Feng H, van de Velde H, Harousseau JL.

http://www.ncbi.nlm.nih.gov/pubmed/23091109